Affiliation:
1. Department of Dermatology DermaMed Clinic Dubai UAE
Abstract
AbstractDyshidrotic palmoplantar eczema or pompholyx is considered to be a part of the spectrum of atopic dermatitis with a significant impact on the quality of life and limited treatment options. Tralokinumab is a new fully human monoclonal antibody which neutralizes interleukin 13, a chief cytokine in itch pathogenesis and skin barrier defects. Tralokinumab is FDA‐approved for the treatment of atopic dermatitis in adults and EMA‐approved for the treatment of atopic dermatitis in adults and adolescents. We, hereby, report a 40‐year‐old female with severe dyshidrotic palmoplantar eczema who was successfully treated with tralokinumab. To the best of our knowledge, this is the first report of the efficacious use of tralokinumab in dyshidrotic eczema.
Reference5 articles.
1. Dupilumab for the treatment of dyshidrotic eczema in 15 consecutive patients
2. Dupilumab in the treatment of dyshidrosis: a report of two cases;Weston GK;J Drugs Dermatol,2018
3. A case of complete resolution of severe plantar dyshidrotic eczema with dupilumab;Nanda S;J Drugs Dermatol,2019
4. Tralokinumab in the treatment of resistant atopic dermatitis: an open‐label, retrospective case series study;Pezollo E;J Eur Acad Dermatol Venereol,2023
5. Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice